Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by SQZ Biotechnologies

SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at Upcoming Investor Conferences
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at Upcoming Investor Conferences
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson’s Disease
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio Updates
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic Advisor
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor Infiltrating Lymphocyte Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate Into Combination With Checkpoint Inhibitors
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at Cantor Global Healthcare Conference
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
SQZ Biotechnologies to Present at Upcoming Health Care Conferences
From SQZ Biotechnologies
Via Business Wire
Tickers SQZ
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.